Today: 9 June 2026
UnitedHealth stock slips after hours — here’s what could move UNH next
6 February 2026
1 min read

UnitedHealth stock slips after hours — here’s what could move UNH next

New York, February 5, 2026, 18:11 EST — After-hours trading

  • UnitedHealth shares slipped 2.7%, ending the day at $268.55; after-hours trading showed minimal movement
  • Medicare Advantage reimbursement proposals continue to cast a shadow over U.S. managed care
  • Investors are focused on the comment deadline set for Feb. 25 and the rate announcement scheduled for April 6

UnitedHealth Group Incorporated (UNH) shares ended Thursday down 2.7%, closing at $268.55, and saw minimal movement after hours. The stock fluctuated between $258.50 and $276.67, with roughly 12.9 million shares traded.

The move ratchets up pressure on the largest U.S. health insurer as investors wrestle with margin forecasts in Medicare Advantage, the privately managed Medicare plans mostly financed by federal funds. For UnitedHealth, even minor tweaks in reimbursement calculations can send earnings estimates swinging.

Attention turns to the government’s draft update for 2027 Medicare Advantage payments. CMS put the net average year-over-year change at just 0.09%, roughly $700 million, but noted the “expected average change” jumps to 2.54% when factoring in the estimated risk-score trend. This highlights how coding and risk adjustment can shift the headline figure. Comments are due by Feb. 25, with the final 2027 Rate Announcement slated for release by April 6. CMS

UnitedHealth trailed a soft market, with the S&P 500 proxy SPY slipping roughly 1.2%. The sector showed mixed moves: Humana (HUM) and CVS Health (CVS) advanced, but Elevance Health (ELV) dropped near 2.4%.

A report from Barron’s on Wednesday highlighted that UnitedHealth’s turnaround is once more being challenged by Medicare policy issues and risk-adjustment hurdles. “That took the wind out of everyone’s sails,” Baird analyst Michael Ha said in the piece. Barron’s

UnitedHealth projected its 2026 revenue to exceed $439 billion, a drop from $447.6 billion expected in 2025, while aiming for adjusted earnings above $17.75 per share. “We confronted challenges directly and finished 2025 as a much stronger company,” CEO Stephen Hemsley said in the company’s outlook. UnitedHealth Group

Investors had expected a bigger jump in Medicare rates. “People were ballparking this flat rate to be closer to 4 to 5%,” said Kevin Gade, chief operating officer at Bahl & Gaynor, which holds UnitedHealth shares, after the proposal dropped. Morningstar analyst Julie Utterback noted the industry will be watching closely to see if CMS revises its assumptions before finalizing the update. Reuters

UnitedHealthcare CEO Tim Noel described the rate as “disappointing” during an earnings call following the notice, Healthcare Finance News reported. Healthcare Finance News

But the numbers can shift, and it’s not just CMS on the hook. If medical costs stay stubbornly high—thanks to greater care usage or pricier drugs—insurers could see their medical care ratios spike, tightening profits even if premium rates get a boost.

Traders will keep an eye on analyst revisions through Friday and into next week, watching closely for any hints that CMS might soften its stance on the tougher elements of the 2027 framework. The next key date is Feb. 25, when the comment period ends, followed by the rate announcement on April 6.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away
Previous Story

Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away

Exxon Mobil stock price slips after oil drops; XOM traders brace for U.S.-Iran talks
Next Story

Exxon Mobil stock price slips after oil drops; XOM traders brace for U.S.-Iran talks

Go toTop